Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at two investor conferences on September 15, 2020. The first event is the Cantor Fitzgerald Virtual Global Healthcare Conference at 9:20 am ET, followed by the H.C. Wainwright & Co. 22nd Annual Global Investment Conference at 4:30 pm ET. Both presentations will be available via live webcast on the company's website, with replays accessible for 90 days post-event. Curis specializes in cancer therapeutics, with ongoing trials for several innovative drugs.
Curis, Inc. (NASDAQ: CRIS) reported its Q2 2020 financial results, highlighting a net loss of $6.7 million, or $0.17 per share, an improvement from a loss of $7.2 million in Q2 2019. Revenue increased to $2.4 million from $2.1 million year-over-year. The biotech firm advanced its clinical pipeline, notably the IRAK4 inhibitor CA-4948, with ongoing studies for non-Hodgkin's lymphoma and acute myeloid leukemia. FDA clearance was received for CI-8993, a new anti-VISTA antibody study. Curis expects cash to support operations through the first half of 2021.
Curis, Inc. (NASDAQ: CRIS) will announce its second quarter 2020 financial results on August 4, 2020, after US market close. A conference call is scheduled for the same day at 4:30 p.m. ET, accessible via phone or the company's website. Curis specializes in developing innovative therapeutics for cancer treatment and has ongoing collaborations focusing on immuno-oncology and precision oncology. The company holds exclusive licenses for several drug candidates currently in clinical trials.